ECE2021 Audio Eposter Presentations Late Breaking (114 abstracts)
Serum endocan level and its correlation with clinicopathologic features in patients with Papillary Thyroid Cancer
Musa Kursad Sener 1 , Mellia Karakose 2 , Muhammet Kocabas 2 , Taha Ulutan Kars 3 , Cihad Solak 4 , Fethi Yönet 5 , Mehmet Emin Gerek 4 , Fatma Hümeyra Yerlikaya Aydemir 6 , Mustafa Kulaksizoglu 2 & Feridun Karakurt 2
1Cihanbeyli State Hospital, The Department of Internal Medicine, Konya, Turkey; 2Necmettin Erbakan University Meram Medical School, The Department of Endocrinology and Metabolism, Konya, Turkey; 3Necmettin Erbakan University, School of Medicine, Department of Internal Medicine, Division of Hematology, Konya, Turkey; 4Konya Numune State Hospital, The Department of Internal Medicine, Konya, Turkey; 5Nigde Omer Halisdemir University Research and Training Hospital, The Department of Internal Medicine, Konya, Turkey; 6Selcuk University Medical School, The Department of Biochemistry, Konya, Turkey
Background
Papillary thyroid cancer (PTC), has a slow progression and good prognosis and is often treatable, but may show recurrence and metastasis. Age, sex, histopathologic variants of PTC, lymphatic or vascular invasion, lymph node involvement are among the factors affecting the occurrence of metastasis. Endocan is produced in vascular endothelial cells, epithelial cells lining the distal tubules of the kidney, submucosal glands of bronchus and lungs. In recent studies, the role of endocan in many cancers has been identified. Serum endocan levels can be used in the early diagnosis of cancers because of the aforementioned characteristics. In addition, many studies have suggested that it can be a molecule of prognostic importance in various cancers. The aim of this study was to compare preoperative serum endocan levels of patients diagnosed with PTC by thyroid FNAB and endocan levels of patients with no malignancy after thyroid FNAB.
Materials and Methods
This study included 48 patients with PTC who underwent total thyroidectomy and 40 age- and sex-matched healthy controls between November 2018 and May 2019. Serum samples were obtained from the patients before surgery. Serum endocan levels of the patients and controls were measured and the results were compared. The relationship between endocan levels and clinicopathological factors was investigated
Results
PTC patients had higher mean serum endocan level than control subjects (45.1 ± 9.6 vs 37.7 ± 8.3 pg/ml, P < 0.001) (Table 1). In PTC patients, there was no relationship between serum endocan levels and histopathologic variant, lymphatic or vascular invasion, surrounding thyroid tissue invasion, lymph node metastasis, surgical margin status, TNM stage and ATA risk stratification group, age and tumor size.
| Parameter | Patient group | Control group | P |
| Gender (M / F) | 38/10 | 36/4 | 0.167 |
| Age | 48.5±14.1 | 48.7±15.8 | 0.932 |
| Weight (kg) | 70.7±9.6 | 72.5±8.9 | 0.372 |
| Height (cm) | 164.8±6.8 | 165.5±6.5 | 0.622 |
| BMI (kg/m2) | 25.9±2.6 | 26.3±2.2 | 0.426 |
| TSH (IU/ml) | 2.1±1.3 | 2.2±1.3 | 0.846 |
| Endocan (pg/ml) | 45.1±9.6 | 37.7±8.3 | <0.001 |
Conclusions
PTC patients had higher mean serum endocan level than control subjects. In PTC patients, there was no relationship between serum endocan levels and histopathologic variant, lymphatic or vascular invasion, surrounding thyroid tissue invasion, lymph node metastasis, surgical margin status, TNM stage and ATA risk stratification group, age and tumor size. This study suggests that serum endocan level can be used as an adjunct test in the diagnosis of PTC in patients with thyroid nodules.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more